CTNNA1 truncating variants define a moderate-penetrance hereditary gastric cancer syndrome
Large-scale clinical and molecular data are now drawing a sharper boundary around CTNNA1 as a hereditary cancer gene. Across 351 carrier families and more than 37,000 non-carrier controls, truncating variants in the gene tracked tightly with diffuse gastric cancer and also showed recurrent lobular breast cancer in some families who would not have met older hereditary diffuse gastric cancer criteria. The central biologic signal is not subtle: truncating transcripts are degraded by nonsense-mediated mRNA decay, and tumors arising in germline truncating carriers lose αE-catenin. In practical terms, the variant class matters, because not every CTNNA1 alteration behaves like a classic loss-of-function allele.
Family-based risk estimates separate truncating from non-truncating alleles
This analysis combined molecular, clinical, and population-level data from 1,308 individuals drawn from 351 CTNNA1-variant carrier families, alongside 37,428 non-carriers of European and American ancestry. Multivariable logistic regression allowed the investigators to compare genotype and phenotype across variant classes rather than treating all CTNNA1 alterations as interchangeable. The separation was clinically consequential. Diffuse gastric cancer risk was eightfold higher in truncating carriers than in non-truncating carriers, and compared with wild-type individuals, gastric cancer risk was sevenfold higher in truncating CTNNA1 carriers and 38-fold higher in CDH1 truncating carriers.
Those numbers place CTNNA1 in a different risk tier from CDH1. The gap is especially important for counseling families who may have assumed both genes carry the same level of penetrance. Here, the cancer burden in CTNNA1 truncating carriers was clearly elevated, but still lower than the burden seen with CDH1 pathogenic or likely pathogenic variants. Risk of gastric cancer was fivefold lower in CTNNA1 truncating carriers than in CDH1 pathogenic or likely pathogenic carriers, and risk of lobular breast cancer was eightfold lower as well. The gene remains clinically meaningful, but the degree of threat is not identical to CDH1.
Nonsense-mediated decay explains why truncating variants behave differently
The mechanistic work helps explain the epidemiology. Using CRISPR/Cas9 CTNNA1-knockout gastric cancer cells and CTNNA1-humanized Drosophila, the study traced the fate of different variant types. Truncating transcripts were degraded by nonsense-mediated mRNA decay, leaving tumors without αE-catenin expression. In the fly model, truncating transcripts were non-functional, while non-truncating transcripts retained function. This distinction supports a biologic model in which truncating alleles produce true loss of function, whereas some non-truncating variants may not abolish protein activity to the same degree.
One sentence captures the core pathophysiology: truncation plus decay removes the protein scaffold that helps maintain epithelial adhesion.
Loss of αE-catenin is not a trivial molecular detail. In diffuse gastric cancer, weakened cell-cell adhesion is part of the tumor’s infiltrative behavior, and disruption of the cadherin-catenin axis fits the diffuse phenotype far better than an expansive intestinal growth pattern. The molecular data therefore align with the clinical pattern rather than standing apart from it. In this syndrome, variant type is tied directly to how the tumor suppressor pathway fails.
Lobular breast cancer extends the phenotype beyond the stomach
The cancer spectrum does not stop at the stomach. Lobular breast cancer recurred among CTNNA1 truncating carriers, including families that did not satisfy hereditary diffuse gastric cancer criteria under older frameworks. That finding matters because it broadens the practical scope of genetic counseling. Families may present through a breast cancer history rather than a gastric cancer pedigree, yet still carry a CTNNA1 truncating variant with meaningful cancer risk.
The study also found an association between macular dystrophy patterned-2 and non-truncating variants, specifically in the αE-catenin M-fragment. This distinct phenotype suggests that non-truncating alleles may carry organ-specific effects outside the cancer setting. For clinicians, it reinforces a simple but often overlooked point: CTNNA1 should not be treated as a single-disease gene. Different variant classes map to different clinical consequences.
Porto criteria sharpen CTNNA1 testing without sacrificing detection
Testing strategy changed as well. Previous criteria were simplified into the Porto criteria, and this revised approach increased CTNNA1-carrier family detection by 9% without loss of performance compared with the HDGC 2020 clinical guidelines. That improvement is modest in absolute terms, but in hereditary cancer genetics, a 9% gain in pickup can represent families newly identified before cancer develops or recurs.
The advantage of a simpler rule set is especially important in real-world referral pathways, where overcomplicated criteria can delay germline testing. By refining who gets tested, the Porto criteria may reduce missed carriers who present with partial phenotypes, incomplete family histories, or mixed gastric and breast cancer patterns. The finding also suggests that older clinical filters may have been too narrow for the full CTNNA1 spectrum.
Surveillance and prophylaxis now depend on variant class, not gene name alone
The practical message from this work is not merely that CTNNA1 is important. It is that CTNNA1 truncating variants behave as a moderate-penetrance hereditary diffuse gastric cancer gene, with substantial gastric cancer risk and recurrent lobular breast cancer in some families, but lower penetrance than CDH1. That places surveillance and risk-reduction decisions on a more precise footing. Families with truncating variants will likely warrant a different conversation from those carrying non-truncating alterations, especially when deciding how aggressively to pursue endoscopic surveillance or prophylactic measures.
The study also leaves a clear boundary line. The evidence supports pathogenicity for truncating variants and a mechanistic role for nonsense-mediated mRNA decay, but non-truncating variants do not automatically belong in the same risk category. Clinical decision-making will need to keep that distinction front and center. A gene-level label alone is no longer enough; the variant class now drives the risk discussion.